3M Drug Delivery Systems and Impel NeuroPharma formed a strategic alliance aimed at advancing Impel’s Precision Olfactory Delivery (POD) technology for the enhanced Central Nervous System (CNS) delivery of drug products.
The alliance with 3M will enable Impel to expedite the development and commercialization of POD technology and accelerate Impel’s internal pipeline into late-stage clinical trials and subsequent global regulatory submissions, according to a press release. As part of the deal, 3M and Impel will collaborate on programs directed to the continued development and commercialization of POD technology. The alliance will leverage 3M’s experience with inhaled and nasal drug delivery devices. Other details of the transaction were not disclosed.
Impel says its POD technology deposits drugs deep into the upper nasal cavity where it can achieve delivery into the brain and central nervous system. POD is a handheld, cost-effective, non-invasive means for delivering CNS therapeutics that can be self-administered by a patient, caregiver, physician, or even family member.
